IMPAX Laboratories, Inc. Confirms Patent Challenge Relating to RENVELA(R), 2.4 g and 0.8 g (For Suspension)

HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of a patent listed by Genzyme Corporation (“Genzyme”) in connection with RENVELA® (sevelamer carbonate for suspension), 2.4 g and 0.8 g.